Mette Bjerre

Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. / Gordin, Daniel; Soro-Paavonen, Aino; Thomas, Merlin C; Harjutsalo, Valma; Saraheimo, Markku; Bjerre, Mette; Forsblom, Carol; Flyvbjerg, Allan; Groop, Per-Henrik; FinnDiane Study Group.

I: Diabetes Care, Bind 36, Nr. 7, 07.2013, s. 1827-33.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Gordin, D, Soro-Paavonen, A, Thomas, MC, Harjutsalo, V, Saraheimo, M, Bjerre, M, Forsblom, C, Flyvbjerg, A, Groop, P-H & FinnDiane Study Group 2013, 'Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes', Diabetes Care, bind 36, nr. 7, s. 1827-33. https://doi.org/10.2337/dc12-2170

APA

Gordin, D., Soro-Paavonen, A., Thomas, M. C., Harjutsalo, V., Saraheimo, M., Bjerre, M., Forsblom, C., Flyvbjerg, A., Groop, P-H., & FinnDiane Study Group (2013). Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. Diabetes Care, 36(7), 1827-33. https://doi.org/10.2337/dc12-2170

CBE

Gordin D, Soro-Paavonen A, Thomas MC, Harjutsalo V, Saraheimo M, Bjerre M, Forsblom C, Flyvbjerg A, Groop P-H, FinnDiane Study Group. 2013. Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. Diabetes Care. 36(7):1827-33. https://doi.org/10.2337/dc12-2170

MLA

Vancouver

Gordin D, Soro-Paavonen A, Thomas MC, Harjutsalo V, Saraheimo M, Bjerre M o.a. Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. Diabetes Care. 2013 jul;36(7):1827-33. https://doi.org/10.2337/dc12-2170

Author

Gordin, Daniel ; Soro-Paavonen, Aino ; Thomas, Merlin C ; Harjutsalo, Valma ; Saraheimo, Markku ; Bjerre, Mette ; Forsblom, Carol ; Flyvbjerg, Allan ; Groop, Per-Henrik ; FinnDiane Study Group. / Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. I: Diabetes Care. 2013 ; Bind 36, Nr. 7. s. 1827-33.

Bibtex

@article{e2634915c8f94517a54d314c358e91bd,
title = "Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes",
abstract = "OBJECTIVE Osteoprotegerin (OPG) is involved in the process of vascular calcification. We investigated whether OPG is associated with the development and progression of diabetes complications in adults with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS Serum OPG was measured in 1,939 adults with T1D participating in the Finnish Diabetic Nephropathy (FinnDiane) Study. Patients with end-stage renal disease (dialysis or transplantation) at baseline were excluded from analysis. Data on cardiovascular (CV) events and mortality during follow-up were verified from hospital discharge registries (ICD codes) and the Finnish National Death Registry, respectively. The follow-up time was 10.4 ± 2.0 (mean ± SD) years. RESULTS Only patients with macroalbuminuria and/or renal impairment had elevated OPG concentrations, when compared with participants without overt kidney disease. Patients with retinopathy or CV disease also had higher OPG concentrations, but this was attributable to their higher frequency of chronic kidney disease. OPG predicted an incident CV event (hazard ratio 1.21 [95% CI 1.01-1.45]; P = 0.035) and peripheral vascular disease/amputation events (1.46 [1.13-1.88]; P = 0.004) during follow-up. CONCLUSIONS We showed that serum OPG is an independent predictor of CV complications. OPG may be directly involved in extraosseous calcification, resulting in stiffening of the arteries and subsequent vascular insufficiency in patients with T1D.",
author = "Daniel Gordin and Aino Soro-Paavonen and Thomas, {Merlin C} and Valma Harjutsalo and Markku Saraheimo and Mette Bjerre and Carol Forsblom and Allan Flyvbjerg and Per-Henrik Groop and {FinnDiane Study Group}",
year = "2013",
month = jul,
doi = "10.2337/dc12-2170",
language = "English",
volume = "36",
pages = "1827--33",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "7",

}

RIS

TY - JOUR

T1 - Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes

AU - Gordin, Daniel

AU - Soro-Paavonen, Aino

AU - Thomas, Merlin C

AU - Harjutsalo, Valma

AU - Saraheimo, Markku

AU - Bjerre, Mette

AU - Forsblom, Carol

AU - Flyvbjerg, Allan

AU - Groop, Per-Henrik

AU - FinnDiane Study Group

PY - 2013/7

Y1 - 2013/7

N2 - OBJECTIVE Osteoprotegerin (OPG) is involved in the process of vascular calcification. We investigated whether OPG is associated with the development and progression of diabetes complications in adults with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS Serum OPG was measured in 1,939 adults with T1D participating in the Finnish Diabetic Nephropathy (FinnDiane) Study. Patients with end-stage renal disease (dialysis or transplantation) at baseline were excluded from analysis. Data on cardiovascular (CV) events and mortality during follow-up were verified from hospital discharge registries (ICD codes) and the Finnish National Death Registry, respectively. The follow-up time was 10.4 ± 2.0 (mean ± SD) years. RESULTS Only patients with macroalbuminuria and/or renal impairment had elevated OPG concentrations, when compared with participants without overt kidney disease. Patients with retinopathy or CV disease also had higher OPG concentrations, but this was attributable to their higher frequency of chronic kidney disease. OPG predicted an incident CV event (hazard ratio 1.21 [95% CI 1.01-1.45]; P = 0.035) and peripheral vascular disease/amputation events (1.46 [1.13-1.88]; P = 0.004) during follow-up. CONCLUSIONS We showed that serum OPG is an independent predictor of CV complications. OPG may be directly involved in extraosseous calcification, resulting in stiffening of the arteries and subsequent vascular insufficiency in patients with T1D.

AB - OBJECTIVE Osteoprotegerin (OPG) is involved in the process of vascular calcification. We investigated whether OPG is associated with the development and progression of diabetes complications in adults with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS Serum OPG was measured in 1,939 adults with T1D participating in the Finnish Diabetic Nephropathy (FinnDiane) Study. Patients with end-stage renal disease (dialysis or transplantation) at baseline were excluded from analysis. Data on cardiovascular (CV) events and mortality during follow-up were verified from hospital discharge registries (ICD codes) and the Finnish National Death Registry, respectively. The follow-up time was 10.4 ± 2.0 (mean ± SD) years. RESULTS Only patients with macroalbuminuria and/or renal impairment had elevated OPG concentrations, when compared with participants without overt kidney disease. Patients with retinopathy or CV disease also had higher OPG concentrations, but this was attributable to their higher frequency of chronic kidney disease. OPG predicted an incident CV event (hazard ratio 1.21 [95% CI 1.01-1.45]; P = 0.035) and peripheral vascular disease/amputation events (1.46 [1.13-1.88]; P = 0.004) during follow-up. CONCLUSIONS We showed that serum OPG is an independent predictor of CV complications. OPG may be directly involved in extraosseous calcification, resulting in stiffening of the arteries and subsequent vascular insufficiency in patients with T1D.

U2 - 10.2337/dc12-2170

DO - 10.2337/dc12-2170

M3 - Journal article

C2 - 23801795

VL - 36

SP - 1827

EP - 1833

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 7

ER -